Current Report Filing (8-k)
April 10 2019 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): April 8, 2019
Rennova
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
001-35141
|
|
68-0370244
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
400
S. Australian Avenue, Suite 800, West Palm Beach,
Florida
|
|
33401
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
|
(561)
855-1626
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
3.03. Material Modification to Rights of Security Holders.
As
previously announced, Rennova Health, Inc. (the “Company”) issued Series B Common Stock Purchase Warrants on March
21, 2017 and September 19, 2017, each with a term of 18 months. The terms of each of such Warrants had been extended to June 2019.
On March 27, 2019, the terms of such Warrants were further extended for 90 days.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
The
Board of Directors of the Company appointed Jonathan Immordino as our Chief Financial Officer effective April 8, 2019. Mr. Immordino,
age 56, had served as the Interim Chief Financial Officer of Susan B. Allen Memorial Hospital, a not-for-profit, general
acute-care medical facility in El Dorado, Kansas, since August 2018. From December 2017 to June 2018, he was the Interim
Chief Financial Officer of Rockledge Regional Medical Center, a full-service 298-bed acute care hospital in Rockledge, Florida.
Mr. Immordino served as Assistant Vice President of Finance of Inova Fairfax Health System, the largest hospital in Northern Virginia,
from December 2015 through December 2017. Previously, from December 2013 to December 2015, he was the Interim Chief Financial
Officer of the Health Care District of Palm Beach County, Florida.
Mr.
Immordino will be paid $250,000 per annum and will be eligible for a bonus of up to $50,000 based on the achievement of specific
performance goals to be agreed. He also will be entitled to participate in any stock option plan that may be implemented by the
Company. If Mr. Immordino is terminated without cause between 90 days and one year after appointment, he will receive three months’
salary and if he is terminated without cause after one year after appointment he will receive six months’ salary.
Mr.
Immordino has no family relationship with any of the executive officers or directors of the Company.
A
copy of the press release issued by the Company announcing Mr. Immordino’s appointment is attached hereto as Exhibit 99.1
and is incorporated by reference herein.
Marlene
McLennan, the former Chief Financial Officer, has transitioned to the position of Executive Vice President of Hospital Operations.
Item
9.01. Financial Statements and Exhibits
.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
April 10, 2019
|
RENNOVA
HEALTH, INC.
|
|
|
|
|
|
|
By:
|
/s/
Seamus Lagan
|
|
|
|
Seamus
Lagan
|
|
|
|
Chief
Executive Officer
|
|
|
|
(principal
executive officer)
|